WHO approves cheaper birth control injection from Incepta Pharmaceuticals

ByEnigma 808

The World Health Organization (WHO) has approved a lower-cost generic version of the popular birth control injection, Medogen SubQ, developed by Incepta Pharmaceuticals. This approval, announced on October 3, allows for more affordable access to the three-month injection, DMPA-SC, which was previously available under Pfizer’s brand name Sayana Press. The approval means the product meets global standards for safety, quality, and effectiveness, making it eligible for distribution through international health programs.

With support from the Children’s Investment Fund Foundation and the Bill & Melinda Gates Foundation, this approval introduces a second major supplier to the global market, which is expected to reduce prices and improve reliability. This development is crucial, as over 250 million women, mostly in low-income countries, still lack access to modern contraceptives. Health experts believe that the wider availability of DMPA-SC will expand options for women, especially in underserved communities.

In Uganda, where there is a high demand for family planning, the approval is seen as a significant step forward. WHO’s approval will help improve access to contraceptives and expand self-care options. This milestone is also expected to help secure stable contraceptive supplies and uphold women’s reproductive rights globally.

Author

  • Enigma XO avatar (80x80)

    Besides writing and being a content creator, Enigma 808 sometimes likes to watch paint dry on walls, listening to ASMR while timing snails racing. Such is life.